Comparison of furosemIde with hypertonic saline to carperitide in the treatment of acute decompensated heart failure

Comparison of furosemIde with hypertonic saline to carperitide in the treatment of acute decompensated heart failure - CONFIRM ADHF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011553

Enrollment

400

Registered

2013-09-01

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute decompensated heart failure

Interventions

Hypertonic saline with low dose furosemide group: continuous infusion of 1.6-1.8% salin with 8% furosemide at the sppeed of 20.3 ml/h for 72 hours. Carperitide with low dose furosemide group: con

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. age 20 and over 2. can obtain written informed concent 3. Systolic BP: 100 mmHg and more 4. eGFR: 15 ml/min/1.73 m2 and more

Exclusion criteria

Exclusion criteria: 1. Diabetes with poor control (HbA1C > 9%). 2. Critical liver dysfunction. 3. Acute coronary syndrome. 4. Acute life-threating disease. 5. HOCM. 6. Critical lung disease. 7. Pulmonary hypertension not due to heart failure. 8. Has experienced myocardial infarction, cerebral infarction, cerebral hemorahge, PCI, and open heart surgery within 3 months. 9. Needs IABP, PCPS, and CRRT. 10. Needs intibation for respiratory management. 11. Hypernatremia (148mEq/l and more) 12. can not obtein body weight 13. Critical cerebrovascular disease. 14. Has already administered inotrope, PDE III, and carperitide. 15. Considered inappropriate for the entry of the study by physician.

Design outcomes

Primary

Measure	Time frame
weight reduction from the start of the study to 72 hours after the start	—

Secondary

Measure	Time frame
1. Improvement in edema at 72 hours after start of study. 2. Dyspnea at 6, 24 and 72 hours after the satrt of the study. 3. Urinary volume for 72 hours. 4. Change in renal function. 5. Earlier termination of continuous infusion therapy due to clinical improvement. 6. Need of additional dose of furosemide, inotrope, PDE III inhibitor, CRRT, assisted circulation devices, NPPV and intubation. 7. Occurrence of life-threatening arrhythmia 8. Hospitalization due to worsening heart failure and/or mortality by 30 days and 180 days	—

Measure

Time frame

1. Improvement in edema at 72 hours after start of study. 2. Dyspnea at 6, 24 and 72 hours after the satrt of the study. 3. Urinary volume for 72 hours. 4. Change in renal function. 5. Earlier termination of continuous infusion therapy due to clinical improvement. 6. Need of additional dose of furosemide, inotrope, PDE III inhibitor, CRRT, assisted circulation devices, NPPV and intubation. 7. Occurrence of life-threatening arrhythmia 8. Hospitalization due to worsening heart failure and/or mortality by 30 days and 180 days

—

Countries

Japan

Contacts

Public ContactHirotani, Shinichi

Hyogo College of Medicine Division of Cardiovasucular Medicine

hirotani@hyo-med.ac.jp0798-45-5-6553

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026